Overview

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Status:
Active, not recruiting

Trial end date:
2022-08-26

Target enrollment:

Participant gender:

Summary

This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition compared to placebo in elderly patients with T2DM.

Phase:

Phase 4

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Empagliflozin